[PDF][PDF] Phase I, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered Ad5CMV-p53, an Adenoviral Vector Containing the Wild-Type p53 …
AW Tolcher, D Hao, J de Bono, A Miller… - Journal of clinical …, 2006 - researchgate.net
AW Tolcher, D Hao, J de Bono, A Miller, A Patnaik, LA Hammond, L Smetzer…
Journal of clinical oncology, 2006•researchgate.netPurpose The purpose of this study was to assess the feasibility of administering Ad5CMV-
p53, an adenoviral vector containing the wild-type p53 gene to patients with advanced
malignancies, characterize the pertinent pharmacokinetic parameters, identify evidence of
viral uptake in both normal and tumor tissue, and seek evidence of antitumor activity.
p53, an adenoviral vector containing the wild-type p53 gene to patients with advanced
malignancies, characterize the pertinent pharmacokinetic parameters, identify evidence of
viral uptake in both normal and tumor tissue, and seek evidence of antitumor activity.
Purpose
The purpose of this study was to assess the feasibility of administering Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene to patients with advanced malignancies, characterize the pertinent pharmacokinetic parameters, identify evidence of viral uptake in both normal and tumor tissue, and seek evidence of antitumor activity.
researchgate.net